CD BioGlyco launched its Therapeutic Nucleic Acid Development Platform. The company says the platform combines nucleic acid synthesis and delivery into a single service. Most platforms only handle one or the other, according to CD BioGlyco. "We built this to save researchers time," said Anna, project leader at CD BioGlyco.
The platform was launched to solve three main problems: stability inside...
English
العربية
Français
Español
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt